4-(甲基磺酰基)苯肼盐酸盐 | 17852-67-4

• 物质功能分类: 化学试剂 - 有机试剂 - 肼
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(甲基磺酰基)苯肼盐酸盐
• 中文别名: 1-(4-(甲磺酰基)苯基)肼盐酸盐；4-甲基磺酰苯肼盐酸盐；4-甲砜基苯肼盐酸盐
• 英文名称: 4-(methylsulfonyl)phenylhydrazine hydrochloride
• 英文别名: (4-methanesulfonylphenyl)hydrazine hydrochloride；p-methylsulfonylphenylhydrazine hydrochloride；4-methylsulphonylphenylhydrazine hydrochloride；p-methanesulfonylphenylhydrazine hydrochloride；4-(methanesulphonyl)phenylhydrazine hydrochloride；1-(4-methanesulfonyl-phenyl)-hydrazine hydrochloride；(4-methylsulfonylanilino)azanium;chloride
• CAS: 17852-67-4
• 化学式: C₇H₁₀N₂O₂S*ClH
• 分子量: 222.696
• InChiKey: QVCMFSJTNVQJFG-UHFFFAOYSA-N

物化性质

• 熔点：
  202 °C
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2928000090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存于阴凉干燥处

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(Methylsulfonyl)phenylhydrazine, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Methylsulfonyl)phenylhydrazine, HCl
CAS number: 17852-67-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2S.ClH
Molecular weight: 222.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(甲基磺酰基)苯肼盐酸盐 在 lithium aluminium tetrahydride 、 偶氮二甲酸二异丙酯 、 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 三苯基膦 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 mineral oil 为溶剂， 反应 35.0h， 生成 2-{3-[1-(4-methanesulfonylphenyl)-5-phenyl-1H-pyrazol-3-yl]-propyl}-isoindole-1,3-dione
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase

  摘要：

  A series of dual inhibitors containing a 1,5-diarylpyrazole and a urea were designed, synthesized, and evaluated as novel COX-2/sEH dual:inhibitors in vitro using recombinant enzyme assays and in vivo using a lipopolysaccharide (LPS) induced model of pain in rats. The best inhibition potencies and selectivity for sEH and COX-2 over COX-1 were obtained with compounds (21b, 211, and 21j) in which both the 1,5-diaryl-pyrazole group aid the urea group are linked with a three-methylene group. Compound 21i showed the best pharmacokinetic profiles in both mice and rats (higher AUC and longer half life). Following subcutaneous administration at 10 mg/kg, compound 21i exhibited antiallodynic activity that is more effective than the same dose of either a COX-2 inhibitor (celecoxib) or a sEH inhibitor (t-AUCB) alone, as well as coadministration of:both inhibitors. Thus, these novel dual inhibitors exhibited enhanced in vivo antiallodynic activity in a nociceptive behavioral assay.

  DOI：

  10.1021/jm2001376
• 作为产物：
  描述：

  4-溴苯甲砜 在 potassium phosphate 、 copper(l) iodide 、 N,N'-二(2,6-二甲基苯基)草酰胺 、 十六烷基三甲基溴化铵 、 一水合肼 、 盐酸 作用下， 以 水 为溶剂， 反应 0.25h， 以0.444 g的产率得到4-(甲基磺酰基)苯肼盐酸盐
  参考文献：
  名称：

  CuI / BMPO催化卤代芳烃与水合肼的交叉偶联合成芳族肼

  摘要：

  的N，N-双（2,6-二甲基苯基）草酰胺，发现作为一个强大的配体对Cu催化的与水合肼芳基卤化物的交叉耦合，从而导致的各种芳基肼的形成在80 ö用C在K 3 PO 4和4 mol％的十六烷基三甲基溴化铵的帮助下，从芳基溴化物和芳基碘化物中加入水。在大多数情况下，观察到良好至极好的产量。

  DOI：

  10.1002/cjoc.201800326

文献信息

• Synthesis of indolo[2,1-<i>a</i>]isoquinoline derivatives <i>via</i> visible-light-induced radical cascade cyclization reactions
  作者：Yun-Long Wei、Jian-Qiang Chen、Bo Sun、Peng-Fei Xu

  DOI：10.1039/c9cc02388g

  日期：——

  We describe a photocatalyzed transformation for the synthesis of the indolo[2,1-a]isoquinoline core structure. This redox neutral reaction features mild reaction conditions and exceptional functional group tolerance. A series of valuable indolo[2,1-a]isoquinoline derivatives bearing various functional groups were synthesized using this method in good to excellent yields.

  我们描述了吲哚[2，1- a ]异喹啉核心结构的合成的光催化转化。该氧化还原中性反应具有温和的反应条件和出色的官能团耐受性。使用该方法以良好至优异的产率合成了一系列带有各种官能团的有价值的吲哚[2，1- a ]异喹啉衍生物。
• [EN] SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS<br/>[FR] ANALOGUES DE PYRAZOLE SUBSTITUÉS EN TANT QU'ANTAGONISTES DE RAR
  申请人：LILLY CO ELI

  公开号：WO2013066640A1

  公开（公告）日：2013-05-10

  The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.

  本发明提供了式I化合物或其药物盐；使用该化合物治疗骨关节炎及其相关疼痛的方法；以及制备该化合物的方法。
• [EN] PYRAZOLONE DERIVATIVES AS NITROXYL DONORS<br/>[FR] DÉRIVÉS DE PYRAZOLONE UTILISÉS EN TANT QUE DONNEURS DE NITROXYLE
  申请人：CARDIOXYL PHARMACEUTICALS INC

  公开号：WO2015183839A1

  公开（公告）日：2015-12-03

  The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

  所披露的主题提供了吡唑酮衍生物化合物，包括这些化合物的药物组合物，包括这些化合物的试剂盒，以及使用这些化合物或药物组合物的方法。具体而言，所披露的主题提供了使用这些化合物或药物组合物治疗心力衰竭的方法。
• [EN] SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS<br/>[FR] PYRAZOLES SUBSTITUÉS AGONISTES DU RÉCEPTEUR FFA4/GPR120
  申请人：AXXAM SPA

  公开号：WO2019175152A1

  公开（公告）日：2019-09-19

  The present invention refers to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. The invention refers also to pharmaceutical compositions comprising these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

  本发明涉及式(I)的化合物或其药学上可接受的盐：式(I)。这些化合物具有FFA4/GPR120受体（FFA4）激动性特性。该发明还涉及包含这些化合物的药物组合物，用于制备它们的化学过程以及它们在治疗或预防与动物（特别是人类）FFA4受体活性相关的疾病中的用途。
• 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
  申请人：LABORATOIRE THERAMEX S.A.

  公开号：EP1099695A1

  公开（公告）日：2001-05-16

  The invention relates to 5-aryl-1H-1,2,4-triazole compounds of the formula : in which R1, R2, R3 and R4 are as defined in the specification. These compounds are potent and selective COX-2 inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds.

  本发明涉及通式为：的5-芳基-1H-1,2,4-三唑化合物，其中R1、R2、R3和R4如说明书中所定义。这些化合物是强效且选择性的COX-2抑制剂。本发明还涉及包含这些化合物的药物组合物。